Travere Therapeutics Inc is at the cutting edge of bio-pharmaceuticals, designing innovative solutions for rare diseases. The firm operates on a global scale.
Part of the competitive pharmaceuticals and biotechnology sector, Travere Therapeutics develops innovative therapies. It strives to tackle rare diseases inadequately addressed by the current healthcare system. Travere Therapeutics is currently working on therapies for focal segmental glomerulosclerosis, classical homocystinuria and Alagille syndrome. It has recently got FDA accelerated approval of a therapy for IgA nephropathy.
Diversify your virtual portfolio by following TVTX shares on eToro.